The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer

BackgroundYoung breast cancer occupies a higher and higher proportion of breast cancer, especially in Asia, and is associated with a more unfavorable prognosis compared with the disease arising in older women. However, the poor prognosis of young breast cancer cannot be fully explained by the clinical and molecular factors.MethodsThis study investigated 1125 Chinese breast cancer patients diagnosed from 2009 to 2013. A data mining of gene expression profiles was performed for the young and older breast cancer patients, identifying significantly differentially expressed genes. Quantitative RT-PCR, Western blotting and immunohistochemistry assay were carried out for the clinical sample validations.ResultsThe investigation firstly displayed that young patients (≤45 years) accounted for 47.6 % (535/1125) of breast cancer, and clinically associated with some unfavorable factors related to poor prognosis, such as invasive pathological type, high tumor grade, lymph node positive, ER negative and triple-negative subtype. Subsequently, 553 significantly differentially expressed genes were identified by the data mining. Of them, a set of genes related to immune function were observed to be up-regulated in young patients with breast cancer. Impressively, the CXCL13 (C-X-C motif chemokine 13) expression level showed the most significant difference (FC = 2.64, P = 8.2 × 10−4). Furthermore, the validations with clinical samples and correlation analysis demonstrated that CXCL13 was indeed highly expressed in young breast cancer and closely associated with some prognostic factors including lymph node positive and ER negative.ConclusionThis is the first to indicate the clinical relevance of CXCL13 to young breast cancer and represents a potential therapeutic target for young breast cancer.

[1]  G. Vlastos,et al.  Survival of young and older breast cancer patients in Geneva from 1990 to 2001. , 2005, European journal of cancer.

[2]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[5]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Seed,et al.  A PCR primer bank for quantitative gene expression analysis. , 2003, Nucleic acids research.

[7]  N. Longo,et al.  Clinical significance of CXCR3 and CXCR4 expression in primary melanoma , 2005, International journal of cancer.

[8]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  Rakesh K. Singh,et al.  CXCL8 and its cognate receptors in melanoma progression and metastasis. , 2010, Future oncology.

[10]  Ku-Sang Kim,et al.  Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort , 2013, Breast Cancer Research and Treatment.

[11]  Yuntao Xie,et al.  BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer , 2009, Breast Cancer Research and Treatment.

[12]  S. Narula,et al.  Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. , 2001, Cytokine.

[13]  V. Pistoia,et al.  CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow , 2008, Cancer Immunology, Immunotherapy.

[14]  J. Rodriguez-Sierra,et al.  Younger women with breast carcinoma have a poorer prognosis than older women , 1996, Cancer.

[15]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[16]  A. Jauch,et al.  Breast cancer in young women (≤35 years): Genomic aberrations detected by comparative genomic hybridization , 2003, International journal of cancer.

[17]  Yan Zhou,et al.  The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. , 2005, Carcinogenesis.

[18]  L. Coussens,et al.  Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.

[19]  V. Malhotra,et al.  CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis , 2013, Breast Cancer Research and Treatment.

[20]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  G. Hortobagyi,et al.  Female patients with breast carcinoma age 30 years and younger have a poor prognosis , 2001, Cancer.

[22]  T. Naab,et al.  Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. , 2007, The Journal of surgical research.

[23]  J. Marks,et al.  Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors , 2008, PloS one.

[24]  S. Ahn,et al.  Do Very Young Korean Breast Cancer Patients Have Worse Outcomes? , 2007, Annals of Surgical Oncology.

[25]  C. Bokemeyer,et al.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients , 2008, British Journal of Cancer.

[26]  V. Malhotra,et al.  Erratum to: CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis , 2016, Breast Cancer Research and Treatment.

[27]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  R. Strieter,et al.  CXC chemokines in cancer angiogenesis and metastases. , 2010, Advances in cancer research.

[29]  B. Sipos,et al.  The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. , 2006, Cancer research.

[30]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[31]  A. Zlotnik.  Chemokines in neoplastic progression. , 2004, Seminars in cancer biology.

[32]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[33]  C. Shapiro,et al.  Trends in breast cancer presentation and care according to age in a single institution. , 2004, American journal of surgery.

[34]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Ghaderi,et al.  Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients. , 2012, European cytokine network.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[37]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Carvalho,et al.  Triple‐negative breast carcinomas are a heterogeneous entity that differs between young and old patients , 2010, Clinics.

[39]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[40]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  L BenitezSoto.  Breast cancer statistics , 1954 .

[42]  J. Stec,et al.  A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. , 2005, Endocrine-related cancer.

[43]  A. Ben-Baruch,et al.  Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. , 1999, Cancer research.

[44]  Hai Zhang,et al.  GenCLiP 2.0: a web server for functional clustering of genes and construction of molecular networks based on free terms , 2014, Bioinform..

[45]  M. Friedlander,et al.  Breast cancer in young women and its impact on reproductive function , 2009, Human reproduction update.

[46]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[47]  David M. Thomas,et al.  The distinctive biology of cancer in adolescents and young adults , 2008, Nature Reviews Cancer.

[48]  P. Dhawan,et al.  Role of CXCL1 in tumorigenesis of melanoma , 2002, Journal of leukocyte biology.

[49]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[50]  L Collette,et al.  Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? , 2003, European journal of cancer.

[51]  M. Bonnen,et al.  The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"? , 2006, International journal of radiation oncology, biology, physics.

[52]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[53]  P. Johnson,et al.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells , 2010, Molecular Cancer.

[54]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[56]  P. Johnston,et al.  Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer , 2005, Clinical Cancer Research.

[57]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[58]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Jin Zhao,et al.  GenCLiP: a software program for clustering gene lists by literature profiling and constructing gene co-occurrence networks related to custom keywords , 2008, BMC Bioinformatics.

[61]  Yan Zhou,et al.  The chemokine GRO-α (CXCL1) confers increased tumorigenicity to glioma cells , 2005 .

[62]  I. Smith,et al.  Breast cancer in adolescents and young women. , 2003, European journal of cancer.

[63]  N. Pavlidis,et al.  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. , 2012, Clinical breast cancer.

[64]  M. Keating,et al.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.

[65]  J. Bergh,et al.  Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.

[66]  I. Bleiweiss,et al.  Stage 0 to stage III breast cancer in young women. , 2000, Journal of the American College of Surgeons.

[67]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[68]  E. Nice,et al.  Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection , 2013, Journal of Translational Medicine.

[69]  G. Stamp,et al.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. , 1997, The American journal of pathology.

[70]  G. Stamp,et al.  The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.

[71]  Jason G. Cyster,et al.  A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1 , 1998, Nature.

[72]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[73]  A. Darzi,et al.  Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.

[74]  A. Bleyer,et al.  Breast cancer before age 40 years. , 2009, Seminars in oncology.

[75]  M. Baggiolini,et al.  B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5 , 1998, The Journal of experimental medicine.

[76]  Rohaizak Muhammad,et al.  Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. , 2010, Pathology, research and practice.

[77]  A. Hutcheon,et al.  Breast cancer in women aged 35 and under: prognosis and survival. , 2002, Journal of the Royal College of Surgeons of Edinburgh.

[78]  Wanjun Chen,et al.  Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression , 2011, International journal of biological sciences.

[79]  Vivek Aggarwal,et al.  Spectrum of Breast Cancer in Asian Women , 2007, World journal of surgery.